Abiopharma

New Form SCHEDULE 13G/A - Forte Biosciences, Inc. Filed: 2025-09-05 AccNo: 0001623632-25-001195 Size: 45 KB

New Form 6-K/A - RedHill Biopharma Ltd. Filed: 2025-09-05 AccNo: 0001558370-25-011890 Size: 2 MB

New Form 10-K - iBio, Inc. Filed: 2025-09-05 AccNo: 0001558370-25-011888 Size: 16 MB

Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

New Form 6-K - Haleon plc Filed: 2025-09-05 AccNo: 0001654954-25-010432 Size: 78 KB

MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic Year

Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts

New Form 8-K - PALISADE BIO, INC. Filed: 2025-09-05 AccNo: 0001493152-25-012687 Size: 248 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Director Williams Donald Allen 🟢 acquired 64.4K shares (1 derivative) of PALISADE BIO, INC. (PALI) Transaction Date: Sep 04, 2025 | Filing ID: 012693

Director Wei Binxian 🟢 acquired 18.8K shares (1 derivative) of PALISADE BIO, INC. (PALI) Transaction Date: Sep 04, 2025 | Filing ID: 012692

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need

Sarepta Therapeutics anuncia a los destinatarios de Route 79, el Programa de Becas de Duchenne, para el año académico 2025-2026